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Abstract
Background: In 2004, an anti-tuberculosis (TB) drug resistance survey in Heilongjiang province, China, enrolled 1574 (79%)
new and 421 (21%) retreatment patients. Multi-drug resistant (MDR) TB was detected in 7.2% of new and 30.4% of
retreatment patients. All received treatment with standardized first-line drug (FLD) regimens.
Methodology/Principal Findings: We report treatment outcomes of the 2004 cohort, and long-term outcomes as assessed
in the second half of 2008. The reported cure rate for MDR-TB patients was 83% (94/113) among new and 66% (85/128)
among retreatment patients (P,0.001). Ten of the 241 MDR-TB patients died during treatment. Of the remaining 231, 129
(56%) could be traced in 2008. The overall recurrence rates among new and retreatment cases were 46% and 66%,
respectively (P=0.03). The overall death rates among new and retreatment cases were 25% and 46%, respectively (P=0.02).
Forty percent of the traced new cases and 24% of the retreatment cases were alive and without recurrent TB (P=0.01). Of
the 16 patients who failed or defaulted from treatment in 2004, only two patients were not re-diagnosed with TB by 2008.
Of the 111 (86%) patients with an initial successful treatment outcome 63 (57%) had developed recurrent TB, 40 (36%) had
died, 27 (24%) of them died of TB. The follow-up period of four years precluded follow-up of all patients. In a highly
conservative sensitivity analysis in which we assumed that all non-included patients were alive and did not have recurrent
TB, the recurrence and death rate were 33% and 21%.
Conclusions/Significance: Documentation of cure based on conventional smear microscopy was a poor predictor of long
term outcomes. MDR-TB patients in Heilongjiang province in China had high recurrence and death rates four years after
treatment with standardized FLD regimens, reinforcing the need for early diagnosis and treatment of MDR-TB, including
assessment of treatment outcomes with more sensitive laboratory methods.
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Introduction
With over 9 million cases and nearly 2 million deaths annually,
tuberculosis (TB) remains a major cause of morbidity and
mortality worldwide [1]. One of the important challenges for
TB control is drug resistance, particularly multidrug resistant
(MDR) and extensively drug-resistant (XDR) TB [2,3]. MDR-TB
is defined as resistance of Mycobacterium tuberculosis isolates to the
two most effective first-line drugs (FLD), i.e., rifampicin and
isoniazid, while XDR-TB has additional resistance to any
fluoroquinolone and at least one of the three injectable second-
line anti-TB drugs (i.e. amikacin, kanamycin, capreomycin) [4,5].
MDR-TB and XDR-TB treatment relies on regimens with less
effective and more toxic second-line drugs (SLD). Failure rates of
MDR-TB patients treated with standard World Health Organi-
zation (WHO) FLD treatment regimens ranged 4%–47% among
new cases and 21%–50% among retreatment cases [6].
China has the second largest number of TB cases in the world
[1], and has a high prevalence of drug resistant TB [7]. The first
national drug resistance survey (DRS) in 2007 reported an overall
MDR-TB prevalence of 8.3%, of which 8% were XDR-TB [8].
Some TB hospitals in China have also reported TB strains that are
resistant to all SLD [9,10].
Heilongjiang province is located in the northeast of China and
has a population of 38.1 million. From 2004–2008, the case
notification rate for all TB was 90–107/100 000 and, for smear-
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control strategy, known as DOTS, was implemented progressively
in this province starting in 1992, and DOTS coverage reached
100% in 1995. In 2004, Heilongjiang province joined the global
project on anti-tuberculosis drug resistance surveillance organized
by the World Health Organization and the International Union
Against Tuberculosis and Lung Disease (WHO/IUATLD). In this
survey, Heilongjiang province contributed 1995 isolates, including
1574 (78.9%) from new TB cases. The prevalence of any drug
resistance in this survey was 36.1% among new cases and 67.5%
among retreatment cases, i.e., TB patients who received at least
one month of anti-TB treatment in the past. The MDR prevalence
was 7.2% among new patients and 30.4% among retreatment
patients. [11].
Up to 50% of MDR-TB patients treated with standardized first-
line DOTS regimens seem to be treated successfully at the end of
the treatment period [6,12–14]. In China, the cure rate of MDR-
TB patients at the end of FLD treatment was relatively high based
on sputum smear microscopy results [15–17]. Whether long term
outcomes in China are also good is unknown, since there is a
paucity of data on long term efficacy of DOTS regimens for
treatment of drug-resistant TB, especially under routine program
conditions [18,19]. To fully evaluate the treatment outcome of
MDR-TB patients, longer follow-up is needed. We report on
treatment outcomes of patients included in a representative drug
resistance survey in Heilongjiang province in China, and on long
term health status of MDR-TB patients as assessed four years after
the end of standardized first-line treatment.
Methods
Ethics statement
The research project was approved by the Chinese Ethical
Committee for TB Operational Research. Written informed
consent was obtained from individuals before an interview was
conducted and sputum samples were collected. If the individual
had died, written informed consent was obtained from the family
member before they were interviewed. Patients and TB hospitals
were informed of the sputum smear, culture, and DST test results,
and MDR-TB patients identified during follow-up were requested
to go to the TB hospital for treatment, including with second-line
drugs.
Drug resistance survey in 2004
For the drug resistance survey (DRS), the ‘‘Guidelines for
surveillance of drug resistance in tuberculosis’’ developed by
WHO/IUATLD were followed [20]. Methods, including those for
quality control of drug susceptibility testing (DST), have been
described in more detail previously [11]. In Heilongjiang province,
30 out of 113 counties and districts were randomly selected, and all
smear-positive cases diagnosed in these sites during the study
period (January through December 2004) were eligible for
inclusion [21]. DST was done for FLDs: isoniazid (H), rifampicin
(R), streptomycin (S), and ethambutol (E).
Treatment regimens and outcomes
As no established program for treating drug-resistant TB existed
in China in 2004, Heilongjiang province followed the National
Tuberculosis Programme (NTP) treatment guidelines for all
patients. Treatment of new smear-positive patients consisted of 2
months of isoniazid, rifampicin, pyrazinamide, and ethambutol
followed by 4 months of isoniazid and rifampicin three times
weekly (2H3R3Z3E3/4H3R3). Patients who had previously re-
ceived at least one month of TB treatment (i.e. retreatment
patients) received 2 months of isoniazid, rifampicin, pyrazinamide,
streptomycin and ethambutol, followed by 6 months of isoniazid,
rifampicin, and ethambutol three times weekly (2H3R3Z3E3S3/
6H3R3E3.). Drug intake was observed at the health facility
throughout treatment.
Treatment outcomes were assessed using international defini-
tions and were recorded in routine treatment registers [22].
Treatment success is defined as either cure or treatment
completed. Cure is defined as a patient who is sputum smear-
negative in the last month of treatment and on at least one
previous occasion. Treatment completed is defined as a patient
who has completed treatment but who does not meet the criteria
to be classified as a cure or a failure. Treatment failure is defined
as a patient who is sputum smear-positive at 5 months or later
during treatment. Default is defined as a patient whose treatment
was interrupted for two consecutive months or more. Transfer out
is defined as a patient who has been transferred to another
recording and reporting unit and whose treatment outcome is
unknown. Death is defined as a patient who dies for any reason
during the course of treatment. The cause of death during TB
treatment was not recorded.
Follow up of MDR-TB patients in 2008
First, all information in the original questionnaires for all
patients included in the DRS was re-checked against medical files,
treatment registers and DRS files. This information included
demographics, treatment history, DST results, and treatment
outcome. Re-checking identified very few discrepancies. Where
discrepancies occurred, we used the information from county/
district TB centers.
Second, staff from TB centers in the counties/districts included
in the DRS were instructed on how to follow-up the 241 patients
that were included in the 2004 DRS and had MDR-TB. County/
district level staff and one provincial staff member interviewed
patients in their home in the period June–December 2008. During
the interview, participants were asked about presence of common
TB symptoms (i.e., cough, haemoptysis, chest pain, fever, fatigue,
anorexia and night sweat), and whether they had been diagnosed
with (recurrent) TB since 2004. Three sputum samples were
collected from all participants for microscopy, culture and DST
using the same methods as in the 2004 survey. If the MDR-TB
patient had been diagnosed with recurrent TB after the end of
treatment, the patient was asked for the name of the hospital or
TB center where the recurrence was diagnosed and the date of
diagnosis. Staff rechecked the smear examination results, diagnosis
and dates with the medical files in the facility. If the MDR-TB
patient had died, family members were interviewed about the time
of death and its cause, and staff would recheck the cause with the
death certificate provided by the hospital. Patients who had TB
registered as a cause of death were assumed to have had recurrent
TB. Patients who had moved were not traced. A random ten
percent of the interviews were repeated by provincial staff not
involved in the initial interview. The re-interviewing results gave
almost identical results except for a few dates.
Data management and analysis
Data were double entered in EpiData 3.1 (The EpiData
Association, Odense, Denmark, 2003–2008) and discrepancies
were checked against the raw data. Analysis was performed using
SPSS 13.0 (SPSS Inc. Chicago, IL, USA). Differences between
groups in the distribution of categorical variables were tested with
the chi-quare test. For the analysis of treatment outcome from
initial TB treatment, we compared patients who were cured to
those that failed, died, or defaulted in a multivariate logistic
Recurrence and Death of MDR-TB
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drug resistance pattern, bacillary load, and number of treatment
episodes. Adjusted odds ratios (OR) and 95% confidence intervals
(CI) were assessed by backward selection of variables included in
the multivariate model, based on the fit of the model as tested with
the likelihood ratio chi-square test (p=0.05).
Results
Outcomes after initial TB treatment
Initial treatment outcome data were available for all 1574 (79%)
new smear-positive TB patients and 421 (21%) retreatment smear-
positive TB patients included in the 2004 survey. The reported
cure rate was 89% (1405/1574) among new and 74% (311/421)
among retreatment patients (P,0.001). The reported cure rate for
MDR-TB patients was 83% (94/113) among new and 66% (85/
128) among retreatment patients (P,0.001) (Figure 1).
Among new patients, those with a sputum smear grade 4+ at
diagnosis (OR=0.6, 95% CI 0.4–0.9) and multidrug resistance
(OR=0.5, 95% CI 0.3–0.9) were less likely to be cured. Among
retreatment patients, those living in a city (OR=0.5, 95% CI 0.3–
0.8), with at least two previous TB treatment episodes (OR=0.5,
95% CI 0.3–0.8), and with multidrug resistance (OR=0.5, 95%
CI 0.3–0.8) were less likely to be cured.
Follow up of MDR-TB patients
Among 241 new and retreatment patients with MDR-TB, 10
(4%) died during treatment. We attempted to trace the remaining
231 patients. We were able to interview 129 (56%) patients or their
household members. The average duration between the end of
treatment and follow up was 47 months (range 42–54) for new
cases and 45 months (range 41–52) for retreatment cases. Reasons
for non-inclusion were: having transferred out (n=46, 19%),
working somewhere else as a migrant worker (n=28, 12%), lost
(n=21, 9%), and refusal to participate (n=7, 3%) (Table 1).
Among the 129 cases traced, 79 (61%) were again diagnosed
with TB after 2004. Of these 79 patients with recurrent TB, 36
(46%) died of TB and 30 (38%) were found to be sputum smear or
culture positive at the time of interview. Of the 16 patients who
failed or defaulted from treatment in 2004, only two patients were
not re-diagnosed with TB (Table 1).
Of the 129 traced MDR-TB patients, 111 (86%) were recorded
in the TB register as having been successfully treated after
diagnosis in 2004 (Table 1). Of those 111, 63 (57%) had a
documented recurrence of TB. Most of the 63 patients with
recurrent TB either died from TB (27; 43%) or were sputum
smear or culture positive at the time of the interview (23; 37%).
The recurrence rate among those treated successfully in 2004
increased year by year, and the overall recurrence rate among
retreatment cases was significantly greater than the recurrence rate
among new cases (66% vs. 46%, P=0.03). The overall death rate
and death rate due to TB was also greater among retreatment
cases than new cases (46% vs. 25%, P=0.02; 36% vs. 12%,
P=0.003) (Table 2).
It is possible that recurrence and death rates were lower in
patients that could not be traced. If we assume that all patients
who were not followed-up were alive and did not have recurrent
TB, the recurrence rate was 33% (63/194) and the death rate was
21% (40/194). If we assume that only those who were not
followed-up because they were migrant workers were alive and did
not have recurrent TB, the recurrence rate and death rates were
46% (63/136) and 29% (40/136), respectively (Table 3).
Figure 1. Flow chart on numbers of patients included in the anti-tuberculosis drug resistance surveillance in 2004 in Heilongjiang
province, China, and followed up in 2008.
doi:10.1371/journal.pone.0010799.g001
Recurrence and Death of MDR-TB
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In this large study of patients with MDR-TB in China, we found
that patients with MDR-TB who had been declared cured with
first-line anti-TB treatment had a high rate of TB recurrence and
death within 4 years.
As observed in other studies [13], MDR-TB was associated with
an increased risk of failure after standardized first-line drug
treatment. The reported cure rates in Heilongjiang of 83% for new
cases and 66% for retreatment cases are based on smear
microscopy and are high compared to what is observed in other
countries [6,13,14,18], but similar to reports from other Chinese
provinces [15–17]. A possible explanation for the reported high
cure rate of MDR-TB in China might be insufficient sensitivity of
sputum smear examination. Although quality assurance for smear
microscopy has been implemented in China for several years, the
impact of such a program in this Chinese province may have been
inadequate or the sensitivity of microscopy for determining
treatment outcome, regardless of adequate quality assurance,
may be insufficient for patients with (MDR-)TB. Patients with
MDR-TB who receive FLD treatment may have their bacillary
burden lowered just enough to avoid detection by light
microscopy. Newer technologies may be needed. For example,
light-emitting diode (LED) – based fluorescence microscopy (FM)
offers increased sensitivity for the evaluation of sputum smear
samples for TB compared with conventional light microscopy
[23]. Improving classification of TB patients at the end of
treatment may require more vigorous implementation of smear
microscopy quality assurance, implementation of new tools (e.g.,
LED-FM), or implementation of existing but underutilized, tools
(e.g., culture).
Our study reports the largest number of MDR-TB patients with
long-term follow-up after initial treatment with FLD. We found
that the rate of TB recurrence and death was high four years after
MDR-TB patients were judged to have been cured, regardless of
assumptions that we made in our analysis. Including only those
patients with follow-up data, we found that the rate of recurrence
was 56% and death 36%; making the highly conservative
assumption that all non-included patients were alive and did not
have recurrent TB, the recurrence rate and death rate were 33%
and 21%, respectively.
In the first year after treatment, 15% of the MDR-TB patients
that were successfully treated had a recurrence of TB and 10%
died. Both the TB recurrence and death rates in new cases
diagnosed with MDR were lower than in retreatment cases
diagnosed with MDR. It is possible that retreatment patients had
more extensive drug resistance at the time of their 2004 treatment
episode, making them less likely to have any bacillary load
reduction from FLD treatment.
Our study has important implications for TB control in China.
High rates of recurrence and death impact the patient and, even
more important, increase the number of persons in the
community with infectious MDR-TB. As would be expected
treatment with FLD is highly ineffective in curing MDR-TB even
if the reported cure rate is high. In regions with a high prevalence
of drug-resistance, such as this province in China, drug-
susceptibility testing will need to be scaled up. At a minimum,
such testing should be performed in all patients at high risk of
MDR-TB, such as known contacts of MDR-TB patients and re-
treatment patients, and may need to be rapidly scaled up to all
patients, depending on the community prevalence of MDR-TB
and available resources.
There are several limitations to our study. The main
limitation is that only slightly more than half of patients could
be included in the follow-up study, which may have led to an
overestimation of recurrence and death rates. A highly
conservative sensitivity analysis in which we assumed that all
t h en o n - i n c l u d e dp a t i e n t sw e r ea l i v ea n dd i dn o th a v er e c u r r e n t
TB, still showed high recurrence and death rates. This
conservative estimate can be assumed to be an underestimate
of recurrence given the TB incidence among migrant popula-
tions [23,24]. It is possible that we under-estimated TB-related
deaths by only counting as TB-related deaths those that had TB
recorded on their death certificates. We were also not able to
Table 1. Treatment outcome of 241 multidrug resistant tuberculosis patients diagnosed and treated in 2004 and then followed up
in 2008*.
Status at follow-up in 2008 Initial treatment outcome from TB episode in 2004
Cure TC Failure Death Default TO Total (%)
No recurrence 46 2 0 0 2 0 50 (38.8)
- death, not due to TB 12 1 0 0 1 0 14 (5.8)
Recurrence 55 8 9 0 5 2 79 (61.2)
-S S + and/or C+ in 2008 22** 1** 5 0 2 0 30 (23.3)***
- death due to TB 22 5 4 0 3 2 36 (27.9)
Subtotal with follow-up 101 10 9 0 7 2 129 (53.5)
Transferred out 28 3 9 0 2 4 46 (19.1)
Migrant workers 24 1 1 0 1 1 28 (11.6)
Refused 6 1 0 0 0 0 7 (2.9)
Lost 20 0 1 0 0 0 21 (8.7)
Died during treatment in 2004 0 0 0 10 0 0 10 (4.2)
Total 179 15 20 10 10 7 241 (100.0)
TC=Treatment completed; TO=Transferred out; SS+=sputum smear positive; C+=culture positive.
*The data include 113 new and 128 retreatment MDR-TB cases.
**SS+C+: 19; SS2C+:4 .
***SS+C+: 22; SS+C2:2 ;S S 2C+:6 .
doi:10.1371/journal.pone.0010799.t001
Recurrence and Death of MDR-TB
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infection, because we did not perform genotyping of TB strains.
However, in the first year, 15% had recurrent TB which is very
high and most likely due to relapse. Unfortunately, due to
limited resources, non-MDR-TB patients were not followed up.
Therefore, we could not compare long-term outcomes of MDR-
TB patients with the long term outcomes of non MDR-TB
patients. In Beijing, 272 sputum smear positive pulmonary TB
patients treated successfully were followed up for 5 years after
end of treatment. The recurrence and death rates were 3.7%
and 9.4%, respectively, which is much lower than in our study
[25]. This may be due to the much lower prevalence of drug
resistance [26], as also indicated by a low failure rate of 1.6%.
In China as well as in Heilongjiang province, recurrent TB
accounts for 9.0% of all notified smear positive TB cases [1]. In
a recent review, a large degree of variation was found in
tuberculosis recurrence in non MDR-TB patients ranging from
2.8% to 12.3% with WHO recommended DOTS after
successful treatment [27]. A more recent large case-control
study from Hong Kong found intermittent (three times weekly)
treatment to be significantly associated with recurrence when
compared with daily treatment [28]. In China, intermittent
regimens are used, which may contribute to higher recurrence
rates.
In a few pilot areas in China, treatment of drug-resistant TB is
now being implemented through the national TB program. WHO
guidelines recommend treatment with at least 4 drugs with certain
or almost certain effectiveness [29]. Only in these pilot sites and a
few well-developed areas of China is DST performed routinely for
MDR-TB suspects and results used to guide TB treatment. Based
on our study results, we strongly suggest that China rapidly scale-
up access to MDR-TB diagnosis and treatment around the
country, with priority for provinces with high anti-TB drug
resistance prevalence.
In conclusion, MDR-TB patients in Heilongjiang province in
China had high recurrence and death rates four years after
treatment with standardized FLD regimens. Documentation of
cure based on conventional smear microscopy at the end of
treatment was a poor predictor of long-term outcome. Adequate
identification and treatment of MDR-TB patients is urgently
needed in order to improve long-term outcomes and to control the
spread of MDR-TB.
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Table 3. Sensitivity analysis of recurrence and death in 2008
among multidrug resistant tuberculosis patients who were
treated successfully after diagnosis in 2004.
Recurrence Death
n*/N % n/N %
All interviewed cases 63/111 56.8 40/111 36.0
Assuming that migrant
workers did not have recurrent TB
63/136 46.3 40/136 29.4
Assuming that all non-interviewed
cases did not have recurrent TB
63/194 32.5 40/194 20.6
*including 27 cases who died of TB.
doi:10.1371/journal.pone.0010799.t003
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